Fig. 1: Magrolimab binding affinity is reduced in the absence of glutaminyl cyclase, while the cell surface expression levels of CD47 remained unaltered. | Communications Biology

Fig. 1: Magrolimab binding affinity is reduced in the absence of glutaminyl cyclase, while the cell surface expression levels of CD47 remained unaltered.

From: Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody binding

Fig. 1: Magrolimab binding affinity is reduced in the absence of glutaminyl cyclase, while the cell surface expression levels of CD47 remained unaltered.

a Crystal structures of αCD47 clone B6H12 (PDB: 5TZU), human SIRPα (PBD: 5IWL) or magrolimab (PBD: 2JJS, all in blue) with CD47 (gray). Red motif indicated the pGlu-epitope. b Representative histograms of pan-αCD47 antibodies clone B6H12 (1:50) followed by αmouse IgG APC (1:800), αCD47 clone 2D3 FITC (1:40), pGlu-specific recombinant human SIRPα-Fc (1:25) followed by αhuman clone M13 PE (1:100), αCD47 clone CC2C6 APC (1:10,000) and magrolimab (1:40,000) followed by αhuman clone QA19 PE (1:100), unstained (light gray) or secondary only (dark gray) staining on Daudi wildtype (blue) and QPCTL KO cells (red; n = 4). Abbreviations: pGlu, pyroglutamate; US, unstained; Sec, secondary antibody only; KO, knockout.

Back to article page